Cargando…

Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qingqing, Liu, Xiaofei, Zhu, Shiqin, Hu, Xuelei, Niu, Huanmin, Zhang, Xiulei, Zhu, Deyu, Nesa, Effat Un, Tian, Keli, Yuan, Huiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/
https://www.ncbi.nlm.nih.gov/pubmed/29327812
http://dx.doi.org/10.1111/jcmm.13475
_version_ 1783302018824142848
author Xu, Qingqing
Liu, Xiaofei
Zhu, Shiqin
Hu, Xuelei
Niu, Huanmin
Zhang, Xiulei
Zhu, Deyu
Nesa, Effat Un
Tian, Keli
Yuan, Huiqing
author_facet Xu, Qingqing
Liu, Xiaofei
Zhu, Shiqin
Hu, Xuelei
Niu, Huanmin
Zhang, Xiulei
Zhu, Deyu
Nesa, Effat Un
Tian, Keli
Yuan, Huiqing
author_sort Xu, Qingqing
collection PubMed
description Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors than paired sensitive PCa cells, as demonstrated by cell proliferation and apoptosis in vitro and in vivo. Kinetic study revealed that TSA‐induced apoptosis was significantly dependent on enhanced transcription and protein synthesis in an early stage, which subsequently caused ER stress and apoptosis. ChIP analysis indicated that TSA increased H4K16 acetylation, promoting ER stress gene transcription. The changes in Ac‐H4K16, ATF3 and ATF4 were also validated in TSA‐treated animals. Further study revealed the higher enzyme activity of HDACs and an increase in acetylated proteins in resistant cells. The higher nucleocytoplasmic acetyl‐CoA in resistant cells was responsible for elevated acetylation status of protein and a more vigorous growth state. These results strongly support the pre‐clinical application of HDAC inhibitors for treating chemotherapy‐resistant mCRPC.
format Online
Article
Text
id pubmed-5824406
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58244062018-03-01 Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A Xu, Qingqing Liu, Xiaofei Zhu, Shiqin Hu, Xuelei Niu, Huanmin Zhang, Xiulei Zhu, Deyu Nesa, Effat Un Tian, Keli Yuan, Huiqing J Cell Mol Med Original Articles Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors than paired sensitive PCa cells, as demonstrated by cell proliferation and apoptosis in vitro and in vivo. Kinetic study revealed that TSA‐induced apoptosis was significantly dependent on enhanced transcription and protein synthesis in an early stage, which subsequently caused ER stress and apoptosis. ChIP analysis indicated that TSA increased H4K16 acetylation, promoting ER stress gene transcription. The changes in Ac‐H4K16, ATF3 and ATF4 were also validated in TSA‐treated animals. Further study revealed the higher enzyme activity of HDACs and an increase in acetylated proteins in resistant cells. The higher nucleocytoplasmic acetyl‐CoA in resistant cells was responsible for elevated acetylation status of protein and a more vigorous growth state. These results strongly support the pre‐clinical application of HDAC inhibitors for treating chemotherapy‐resistant mCRPC. John Wiley and Sons Inc. 2018-01-12 2018-03 /pmc/articles/PMC5824406/ /pubmed/29327812 http://dx.doi.org/10.1111/jcmm.13475 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Xu, Qingqing
Liu, Xiaofei
Zhu, Shiqin
Hu, Xuelei
Niu, Huanmin
Zhang, Xiulei
Zhu, Deyu
Nesa, Effat Un
Tian, Keli
Yuan, Huiqing
Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title_full Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title_fullStr Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title_full_unstemmed Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title_short Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
title_sort hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor trichostatin a
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/
https://www.ncbi.nlm.nih.gov/pubmed/29327812
http://dx.doi.org/10.1111/jcmm.13475
work_keys_str_mv AT xuqingqing hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT liuxiaofei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT zhushiqin hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT huxuelei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT niuhuanmin hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT zhangxiulei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT zhudeyu hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT nesaeffatun hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT tiankeli hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina
AT yuanhuiqing hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina